Shanghai Pharmaceutical announced that in 2021, its wholly-owned subsidiary Shangyao Xinyi signed the “Original Cooperation Agreement” with Guizhou Shengnuo and Jiangsu Shengnuo for the X842 project, and Shangyao Xinyi received exclusive production and sales rights. On November 18, 2025, Shangyao Xinyi and Shengnuo Biotech signed a “Termination Agreement”. The agreement came into effect after receiving a refund of 110 million yuan. On December 5, Shangyao Xinyi received payment, and the “Original Cooperation Agreement” was automatically terminated. This termination of cooperation will not have a significant impact on the company's and Shanghai Pharmaceutical Xinyi's finances and operations.

Shanghai Pharmaceutical announced that in 2021, its wholly-owned subsidiary Shangyao Xinyi signed the “Original Cooperation Agreement” with Guizhou Shengnuo and Jiangsu Shengnuo for the X842 project, and Shangyao Xinyi received exclusive production and sales rights. On November 18, 2025, Shangyao Xinyi and Shengnuo Biotech signed a “Termination Agreement”. The agreement came into effect after receiving a refund of 110 million yuan. On December 5, Shangyao Xinyi received payment, and the “Original Cooperation Agreement” was automatically terminated. This termination of cooperation will not have a significant impact on the company's and Shanghai Pharmaceutical Xinyi's finances and operations.